Well-known bone-targeted agents, bisphosphonates and the receptor activator of nuclear kappa ligand (RANKL) inhibitor, denosumab, have emerged as effective options for the treatment of breast cancer patients with bone metastases [11,12,13,14,15,16,17,18]. Here, TNFSF11 is linked to breast carcinoma.